Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Zentalis Presented Updated DENALI Part 1b Clinical Data Demonstrating 6.3-Month mDOR And ~35% ORR With Azenosertib Monotherapy In Cyclin E1+ Platinum-Resistant Ovarian Cancer

Author: Benzinga Newsdesk | March 17, 2025 03:17am

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients
On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026
Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody-drug conjugates (ADCs), demonstrating synergistic antitumor effects

Posted In: ZNTL